BPC-157 — Complete Research Guide (2026)
Last updated 2026-06-25
TL;DR
A synthetic pentadecapeptide derived from a protein found in gastric juice. Studied extensively in animal models for tissue-healing effects; no completed human efficacy trials exist.
What is BPC-157?
BPC-157 is a synthetic pentadecapeptide — a 15-amino-acid chain — whose sequence is derived from a protein isolated from human gastric juice. It is sometimes written as PL 14736 in the older inflammatory-bowel-disease literature.
It is important to state the evidence base plainly: nearly all published efficacy data for BPC-157 come from preclinical models (rodent and in-vitro). A 2025 systematic review in the HSS Journal identified 35 preclinical studies but only a single small clinical study, and found no human randomized controlled trials and no clinical safety dataset.
BPC-157 is not approved for human use by the FDA, EMA, or any equivalent regulator. It is sold and discussed as a research chemical.
How does BPC-157 work?
The mechanisms described in animal studies center on angiogenesis (new blood-vessel formation) and modulation of growth-factor signalling. In a rodent muscle- and tendon-healing model, BPC-157 up-regulated vascular endothelial growth factor (VEGF) and promoted angiogenesis, although it showed no direct angiogenic effect in cell culture alone.
In isolated tendon fibroblasts, BPC-157 promoted cell outgrowth, survival under oxidative stress, and dose-dependent migration via the FAK–paxillin pathway. [INFOGRAPHIC: BPC-157 tendon-fibroblast migration pathway]
What does the research say about BPC-157?
- In a rat Achilles-tendon model, BPC-157 promoted tendon-to-bone healing and counteracted corticosteroid-induced impairment of that healing. [4]
- Across multiple administration routes, BPC-157 produced consistent functional, biomechanical and histological ligament-healing improvements versus controls over a 90-day rat study. [3]
- In a muscle/tendon model it stimulated angiogenesis by up-regulating VEGF, an effect the authors linked to improved healing. [2]
[UNIQUE ANALYSIS] Synthesising the six references, the consistent thread is that BPC-157’s evidence is mechanistically interesting but entirely preclinical: angiogenesis and growth-factor modulation are reproduced across independent rodent labs, yet the translation gap to humans remains unbridged. The 2025 systematic review is the most useful single source because it quantifies that gap — 35 animal studies to one small clinical study.
Clinical research & studies
The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.
- [1] The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Chang CH et al., J Appl Physiol 2011. (in-vitro / ex-vivo (tendon fibroblasts))
- [2] Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing — Brcic L et al., J Physiol Pharmacol 2009. (in-vitro + in-vivo (rodent))
- [3] Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — Cerovecki T et al., J Orthop Res 2010. (animal (rat MCL transection))
- [4] Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — Krivic A et al., J Orthop Res 2006. (animal (rat))
- [5] Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease — Sikiric P et al., Inflammopharmacology 2006. (review of animal data)
- [6] Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review — Vasireddi N et al., HSS Journal 2025. (systematic review (35 preclinical + 1 small clinical))
Dosing context
Published studies are animal experiments using intraperitoneal, intramuscular or intragastric routes at doses expressed per kilogram of body weight in rats. These do not translate to a human protocol.
This is not medical advice or a usage recommendation. No validated human dose exists because no human efficacy trial has been completed.
Side effects & safety profile
There is no published human safety dataset for BPC-157. The 2025 systematic review explicitly noted the absence of clinical safety data and flagged BPC-157 as an unapproved substance with compliance implications for athletes (it is monitored in anti-doping contexts).
Because no human pharmacokinetic study establishes a reliable plasma half-life, any specific half-life figure circulating online should be treated as unsubstantiated.
Reported animal studies have not, to date, surfaced major acute toxicity signals — but absence of evidence in rodents is not evidence of human safety.
Stacking & combinations
BPC-157 is frequently discussed alongside TB-500 in recovery contexts, but there is no controlled human study evaluating any combination. Treat all combination claims as unverified.
Finding BPC-157 vendors
Finding BPC-157 vendors
This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.
Choose your country
We never list placeholder vendors. Pick your country to see neutral regulatory context.
User reviews
No reviews yet
Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.
Frequently asked questions
No. BPC-157 is not approved for human use by the FDA, EMA or any equivalent regulator. It is sold as a research chemical.
References
- [1] The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration — Chang CH et al., J Appl Physiol 2011. PMID: 21030672. View sourceStudy: in-vitro / ex-vivo (tendon fibroblasts)BPC-157 promoted tendon-fibroblast outgrowth, survival under oxidative stress and dose-dependent migration via the FAK–paxillin pathway.
- [2] Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing — Brcic L et al., J Physiol Pharmacol 2009. PMID: 20388964. View sourceStudy: in-vitro + in-vivo (rodent)No direct angiogenic effect in culture, but in animals BPC-157 stimulated angiogenesis by up-regulating VEGF.
- [3] Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat — Cerovecki T et al., J Orthop Res 2010. PMID: 20225319. View sourceStudy: animal (rat MCL transection)Consistent functional, biomechanical and histological ligament-healing improvement over 90 days across routes.
- [4] Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation — Krivic A et al., J Orthop Res 2006. PMID: 16583442. View sourceStudy: animal (rat)Enhanced tendon-to-bone healing and counteracted corticosteroid-induced impairment.
- [5] Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease — Sikiric P et al., Inflammopharmacology 2006. PMID: 17186181. View sourceStudy: review of animal dataMaintained gastric vascular integrity and inhibited gastrointestinal lesions in distended-stomach rat models.
- [6] Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review — Vasireddi N et al., HSS Journal 2025. PMID: 40756949. View sourceStudy: systematic review (35 preclinical + 1 small clinical)Benefit is supported almost entirely by animal data; no human RCTs and no clinical safety data were identified.